SIM
IMDX

Sonora Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Sonora Investment Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3
Closed -$178 – 869
2016
Q2 		$178 Hold
3
– – ﹤0.01% 839
2016
Q1 		$268 Buy
+3
New +$266 ﹤0.01% 927

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Sonora Investment Management's IMDX Position: Q3 2016 in Review

Sonora Investment Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2016, closing a stake of 3 shares — an estimated $178 sold.

Sonora Investment Management first reported a position in IMDX in Q1 2016 and held it in 2 quarters. The position peaked at $268 in Q1 2016. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2016.

  • Sonora Investment Management reported no remaining Insight Molecular Diagnostics position as of Q3 2016 after selling out during the quarter.
  • Sonora Investment Management sold 3 Insight Molecular Diagnostics shares in Q3 2016, an estimated $178.
  • Sonora Investment Management first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 2 quarters.
  • Sonora Investment Management's Insight Molecular Diagnostics position peaked at $268 in Q1 2016.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2016.

Based on Sonora Investment Management's 13F filing for Q3 2016, filed 17 Oct 2016.